Paper: Real-World Outcomes with Fedratinib Therapy in Patients Who Discontinued Ruxolitinib for Primary Myelofibrosis

Real-world Outcomes of Fedratinib in Patients with Myelofibrosis who Discontinued Ruxolitinib

Read the full article here

Categories: General Medicine Journals and Societies, General Medicine News, Healthcare Professionals, Latest Headlines
Tweets with this article
DocWire Editors
Real-world Outcomes of Fedratinib in Patients with Myelofibrosis who Discontinued Ruxolitinib

Related Articles